TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Mar 02, 2023 10:45 JST
Source:
Eisai
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan
TOKYO, Mar 02, 2023 - (JCN Newswire) - Biogen Japan Ltd. and Eisai Co., Ltd. announced today the termination of the co-promotion agreement that has been in place since January 2018 for Biogen Japan's multiple sclerosis (MS) treatments TECFIDERA (dimethyl fumarate), TYSABRI (natalizumab, genetic recombinant) and AVONEX (interferon beta 1a, genetic recombinant) in Japan as of March 31, 2023.
The two companies have been jointly engaged in promotional activities for MS treatments in Japan. However, since a certain objective has been achieved regarding penetration of the products into the Japanese market, the two companies decided to terminate this co-promotion agreement. As a result, Biogen Japan will have full responsibility for all operations related to the products after a transition period between the two companies. Upon termination of this agreement, Biogen will pay Eisai 31 million USD.
The termination of this co-promotion agreement does not impact any of the other agreements between Biogen and Eisai.
For more information, visit www.eisai.com/news/2023/news202315.html.
Contacts:
Biogen Japan Ltd.
MEDIA CONTACT:
Public Relations & CSR Department
MOB: +81-(0)70-1501-4315
TEL: +81-(0)3-3275-1745
Eisai Co., Ltd.
MEDIA CONTACT:
Public Relations Department
TEL: +81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea
June 08 2023 12:32 JST
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting
June 02 2023 11:20 JST
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 26 2023 13:15 JST
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
May 25 2023 20:02 JST
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
May 24 2023 17:03 JST
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
May 20 2023 09:20 JST
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
May 16 2023 08:27 JST
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
May 08 2023 10:15 JST
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
April 06 2023 17:32 JST
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal
April 04 2023 12:23 JST
More Press release >>
Latest Press Release
Mitsubishi Motors Premieres the All-New Colt for the European Market
Jun 09, 2023 20:28 JST
TOYOTA GAZOO Racing Unveils "GR H2 Racing Concept" at Le Mans 24 Hours
Jun 09, 2023 18:09 JST
Pilot Project for Lifelog-based Health Services in Muraoka-Fukasawa District
Jun 09, 2023 11:47 JST
Crafted Exclusively for the North American Market, Lexus Celebrates the World Premiere of the All-New TX
Jun 09, 2023 10:00 JST
World Premiere of the All-New Lexus GX
Jun 09, 2023 09:30 JST
Hitachi launches "Hitachi Application Reliability Centers Service" in Japan to enable cloud-native operations to drive both agility and reliability
Jun 08, 2023 16:50 JST
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea
Jun 08, 2023 13:32 JST
MHI Inks MoU with TNB Genco on Clean Energy Technologies to Drive Decarbonization in Malaysia
Jun 07, 2023 15:56 JST
Aiming to Realize an Ever-Better Mobility Society, Toyota Mobility Foundation Selects 12 Teams for 2023 to Work on Activities in the "Mobility for ALL" Category of its Idea Contest
Jun 07, 2023 10:56 JST
JNTO, Mazda Motor Corporation, and TOYOTA GAZOO Racing Jointly Holding "Japan. Endless Discovery." Exhibit on Centenary of Le Mans 24 Hours Race
Jun 06, 2023 17:21 JST
NEC to supply East Micronesia Cable System (EMCS)
Jun 06, 2023 16:18 JST
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
Jun 06, 2023 15:58 JST
Fujitsu 1FINITY Ultra Optical System selected by NTT for next Japan-wide core network
Jun 06, 2023 11:53 JST
Olympus Announces Plan to Establish Digital Excellence Centers Following Acquisition of Cloud-AI Endoscopy Startup Odin Vision
Jun 05, 2023 16:00 JST
Olympus Announces Plan to Establish Digital Excellence Centers Following Acquisition of Cloud-AI Endoscopy Startup Odin Vision
Jun 05, 2023 16:00 JST
Lexus Celebrates the World Premiere of the All-New LBX
Jun 05, 2023 15:35 JST
Mitsubishi Shipbuilding to Launch Technical Studies on Ammonia Fuel Supply System for Marine Engines under Development by WinGD
Jun 05, 2023 13:52 JST
Rovanpera increases lead with podium for TOYOTA GAZOO Racing
Jun 05, 2023 11:02 JST
JCB and Joint Stock Commercial Bank for Investment and Development of Vietnam launch the BIDV JCB Ultimate Credit Card in Vietnam
Jun 02, 2023 16:00 JST
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting
Jun 02, 2023 12:20 JST
More Latest Release >>